Insight

Jul 13, 2024, 19:41

Joshua Zeidner: Subset analyses from QUAZAR study

Joshua Zeidner, Associate Professor at UNC Lineberger, shared on X about a recent paper by Hartmut Döhner et al. titled “Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine” published in ASH Publications.

Authors: Hartmut Döhner, Andrew H. Wei, Gail J. Roboz, Pau Montesinos, Felicitas R. Thol, Farhad Ravandi, Hervé Dombret, Kimmo Porkka, Irwindeep Sandhu, Barry Skikne, Wendy L. See, Manuel Ugidos, Alberto Risueño, Esther T. Chan, Anjan Thakurta, C.L. Beach, Daniel Lopes de Menezes.

Joshua Zeidner commented on X sharing this paper:

“Leukemia Journal Club Happy Hour tackled maintenance therapy with oral Azacitidine in NPM1 mutated AML patients- subset analyses from QUAZAR study- Great discussion with colleagues over.” ․

Source: Joshua Zeidner/X

Alberto Risueño AML Andrew Wei Anjan Thakurta ASH Publications azacitidine Barry Skikne cancer Daniel Lopes de Menezes Esther Chan Farhad Ravandi Felicitas Thol Gail Roboz Hartmut Döhner Hervé Dombret Irwindeep Sandhu Joshua Zeidner Kimmo Porkka Leukemia Leukemia Journal Club Manuel Ugidos NPM1 NPM1 mutation OncoDaily Oncology Pau Montesinos QUAZAR UNC Lineberger Wendy See

MiNK Therapeutics Stock Surges on Breakthrough Testicular Cancer Remission and iNKT Cell Therapy Progress

Tabelecleucel (Ebvallo) FDA Update: Approval Delayed Despite Positive Phase 3 Data

New Paper Alert: Breakthrough iNKT Cell Therapy Achieves Complete Remission in Metastatic Germ Cell Tumor

"God Invented This" - Pat Soon-Shiong on Cancer Discovery

Yüksel Ürün: Science Is Better When It’s Shared